Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
One Percent Rule Checklist For Safer Forex Trading Risk 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
NEW YORK, April 13, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry and a member of the AXIM advisory board, presented at the CannMed 2017 Conference held at the Joseph B. Martin Conference at Harvard Medical School in Boston on April 9-11, 2017.
Dr. Reznik presented a poster entitled “Cannabinoid-based Medicine as a Pivotal Model for Personalized Integrative Care” which was met with considerable interest by the scientific community.
Dr. Ilya Reznik has been a clinical practitioner utilizing medical cannabis in patient treatment for over ten years with documented contributions to the field of neuropsychiatric research. Dr. Reznik joined the AXIM advisory board in December 2016 and will be actively involved with the company’s upcoming clinical program on using cannabis-based solutions to treat drug addiction and early psychosis.
The CannMed Conference is a gathering of the greatest minds in medical cannabis research; where they discussed the work they are doing to better understand the way this remarkable plant works and how their work will shape future cannabis research and development.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media [email protected] P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling [email protected] P. +1646 284-9474 Lucia Domville, Grayling [email protected] P. +1646 284-9416 Corporate Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
